8-K: UroGen Pharma Announces Positive Durability Data for UGN-102 in Bladder Cancer Trial

UroGen Pharma reported positive 12-month duration of response data from its Phase 3 ENVISION trial for UGN-102, a potential treatment for low-grade intermediate risk non-muscle invasive bladder cancer.

Summary

• UroGen Pharma announced positive secondary endpoint data for UGN-102 from the Phase 3 ENVISION trial, focusing on the duration of response (DOR) in patients with low-grade intermediate risk non-muscle invasive bladder cancer (LG-IR-NMIBC).
• The 12-month DOR data, using the Kaplan-Meier estimate, showed that 82.3% of patients who achieved a complete response (CR) at three months after the first UGN-102 instillation maintained that response.
• This is consistent with previous trials, including the Phase 2b OPTIMA II trial (69.9% at nine months) and the Phase 2 ATLAS trial (79.6% at 12 months).
• The ENVISION trial also met its primary endpoint, with a 79.6% CR rate at three months, which is in line with the CR rates observed in the OPTIMA II (65.1%) and ATLAS (64.8%) trials.
• Among patients who achieved a CR at three months in the ENVISION trial, 76.4% maintained a CR at 12 months, and 60.8% of all enrolled patients were still in response at 12 months.
• DOR estimates at 15 and 18 months were both 80.9%, and the predicted median DOR is 40 months based on the Weibull Predicted Curve, although the median DOR was not estimable due to the number of patients remaining in CR.
• The safety profile of UGN-102 in the ENVISION trial was similar to that observed in previous trials, with adverse events typically mild to moderate.
• UroGen initiated the submission of a rolling New Drug Application (NDA) to the FDA in January 2024, and plans to complete the submission in the third quarter of 2024.
• Potential FDA acceptance is expected in the fourth quarter of 2024, with potential approval in the first or second quarter of 2025, depending on whether priority or standard review is granted.
• The company estimates the annual addressable U.S. patient population for LG-IR-NMIBC to be approximately 82,000, with a total addressable market opportunity of over $5.0 billion, assuming a price range of $16,000 to $19,000 per dose.
• UGN-102, if approved, could be an alternative to the current standard of care, trans-urethral resection of bladder tumor (TURBT), which is associated with risks and repeated procedures.

Sentiment

Score: 9

Explanation: The document presents very positive clinical trial results, a large market opportunity, and a clear path to potential FDA approval, indicating a strong positive sentiment.

Positives

• The 12-month duration of response data from the ENVISION trial is very strong at 82.3%.
• The complete response rate of 79.6% at three months is consistent with previous trials.
• The predicted median duration of response of 40 months is very promising.
• UGN-102 has the potential to become the first FDA-approved medicine for LG-IR-NMIBC.
• UGN-102 offers a non-surgical alternative to TURBT, which can reduce the burden on patients.
• The estimated total addressable market opportunity for UGN-102 is over $5.0 billion.
• Patient interviews suggest that UGN-102 has less impact on daily activities compared to TURBT.

Negatives

• The median duration of response was not estimable due to the number of patients remaining in complete response.
• There were some treatment-related adverse events, although they were generally mild to moderate.
• There is no guarantee that the NDA will be approved by the FDA, or that it will be approved on the expected timeline.

Risks

• The ENVISION DOR data may not be sufficient to support the NDA submission for UGN-102.
• Even if the NDA is accepted, there is no guarantee of FDA approval or that it will be approved on the expected timeline.
• Clinical trials may encounter unforeseen delays or safety complications.
• Results from prior trials may not be indicative of future results.
• There are risks associated with commercialization activities and competition in the industry.
• The company's RTGel technology may not perform as expected.
• The company may not be able to attract or retain key personnel.

Future Outlook

The company anticipates completing the NDA submission in Q3 2024, with potential FDA acceptance in Q4 2024 and potential approval in either Q1 or Q2 2025, depending on the review type. UGN-102 has the potential to become the first FDA-approved medicine for LG-IR-NMIBC.

Management Comments

• UroGen is uniquely positioned to transform bladder cancer treatment.
• The company aspires to change the treatment paradigm for bladder cancer.
• UGN-102 has the potential to transform the treatment paradigm in LG-IR-NMIBC.

Industry Context

This announcement is significant as it highlights a potential non-surgical alternative to TURBT for LG-IR-NMIBC, a market with a high recurrence rate and limited treatment options. The positive data could position UroGen as a leader in this space, potentially disrupting the current standard of care.

Comparison to Industry Standards

• The 82.3% 12-month DOR for UGN-102 is very competitive compared to other treatments for LG-IR-NMIBC, which often involve repeated TURBT procedures.
• The 79.6% complete response rate at 3 months is also strong, and is in line with the results from the OPTIMA II and ATLAS trials.
• While direct comparisons to other investigational drugs are difficult without specific data, the results suggest UGN-102 is a promising candidate.
• The predicted median DOR of 40 months is a significant improvement over the typical recurrence rates seen with TURBT alone.
• The safety profile of UGN-102 appears to be favorable compared to more invasive procedures like TURBT, which can have a higher risk of adverse events.

Stakeholder Impact

• Shareholders are likely to react positively to the strong clinical data and potential market opportunity.
• Patients with LG-IR-NMIBC may benefit from a new, non-surgical treatment option.
• Healthcare professionals may have a new tool for managing LG-IR-NMIBC.
• The company's employees may benefit from the potential success of UGN-102.

Next Steps

• The company will complete the NDA submission to the FDA in the third quarter of 2024.
• The company anticipates potential FDA acceptance of the NDA in the fourth quarter of 2024.
• The company expects potential FDA approval in the first or second quarter of 2025, depending on the review type.

Key Dates

Keywords

UGN-102, bladder cancer, LG-IR-NMIBC, duration of response, complete response, ENVISION trial, FDA approval, TURBT, RTGel, non-surgical treatment